

REFERENCES

- Abdel –Fattah M M: (2005)* Surveillance of nosocomial infections at a Saudi Arabian military hospital for a one-year period. Epidemiology and Research Unit, Preventive Medicine Department, Al-Hada Armed Forces Hospital, Taif, Saudi Arabia .GMS Ger Med Sci. **3**:Doc06.
- Abraham E P and Chain E (1940):* "An enzyme from bacteria able to destroy penicillin". Nature. **46**: 837.
- Acar JF and Goldstein FW (1997):* Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis. **24** (suppl 1): S67 – 73.
- Afzal-Shah M, Woodford N and Livermore D M (2001):* Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β -lactamases associated with carbapenem resistance in clinical isolates of *Acinetobacter baumannii*. Antimicrob. Agents Chemother. **45**:583-8.
- Aguita and Maria (2009):* "Combating Bacterial Infection": Phage therapy. Available from: LabNews.co.uk. http://www.labnews.co.uk/printer_friendly.php/2912/combating-bacterial-infection.
- Aires J R and Nickaido H (2005):* Aminoglycosides are captured from both periplasm and cytoplasm by the AcrD multidrug efflux transporter of *Escherichia coli*. J. Bacteriol. **187**: 1923 –9.
- Albertini M T, Benoit C, Berardi L, Berrouane Y, Boisivon A, Cahen P, Cattoen C, Costa Y, Darchis P, Delière E and Demontrond D*

- (2002): Surveillance of methicillin-resistant *Staphylococcus aureus* (MRSA) and Enterobacteriaceae producing extended-spectrum beta-lactamase (ESBL) in Northern France: a five-year multicentre incidence study. Microbiology Surveillance Network of Northern France. J Hosp Infect. Oct; **52**(2):107-13.
- Aleskshun M N and Levy S B (1997):** Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon. Antimicrob. Agents Chemother. **41**: 2067 –75.
- Ambler R P (1980):** The structure of β -lactamases. Philos. Trans. R. Soc. Lond. B. Biol. Sci. **289**:321-31.
- Amyes S G B, Paton R H, Miles R S and Hood J (1992):** Ofloxacin as the standard 4-quinolone in sensitivity tests. Antimicrob. Agents Chemother. **30**:101-2.
- Ananthan S and Subha A (2005):** Cefoxitin resistance mediated by loss of a porin in clinical strains of *Klebsiella pneumoniae* and *Escherichia coli*. Issue .**23** (1):20-23
- Anderson K F, Lonsway D R and Rasheed J K (2007):** Evaluation of methods to identify the *Klebsiella pneumoniae* carbapenemase in Enterobacteriaceae. J Clin Microbiol. **45**: 2723 –25.
- Andrews J, Boswell F J and Wise R (2000):** Evaluation of the Oxoid Aura image system for measuring zones of inhibition with the disc diffusion technique. Antimicrob. Agents Chemother.**46**: 535-40.
- Apfalter P, Assadian O, Kalczyk A, Lindenmann V, Makristathis A and Mustafa S (2002):** Performance of a new chromogenic oxacillin resistance screen medium (Oxoid) in the detection and presumptive

identification of methicillin - resistant *Staphylococcus aureus*. *Diagn Microbiol Infect Dis.* **44**: 209-211.

Arakawa Y, Shibata N, Shibayama K, Kurokawa H, Yagi T, Fujiwara H and Goto M (2000): Convenient test for screening metallo- β -lactamase-producing gram-negative bacteria by using thiol compounds. *J. Clin. Microbiol.* **38**:40-43.

Ardino R C and Murray B E (1990): *Enterococcus* antimicrobial resistance. *Principles and Practice of Infectious Diseases*. 3rd ed. New York, NY: Churchill Livingstone. Update . **2**: (4).

Arias, Cesar A, Murray and Barbara E (2009): "Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge". *New England Journal of Medicine.* **360** (5): 439–43.

Arlet G, Sanson-Le, Pors M J, Rouveau M, Fournier G, Marie O, Schlemmer B and Philippon A (1990): Outbreak of nosocomial infections due to *Klebsiella pneumoniae* producing SHV-4 beta-lactamase. *Eur. J. Clin. Microbiol. Infect. Dis.* **9**:797-803.

Arya S C, Agarwal N, Agarwal S, George S and Singh K (2004): Nosocomial infection: hospital infection surveillance and control. *J Hosp Infect.* **58**(3):242-3.

Azucena E and Mobashery S (2001): Aminoglycosides – modifying enzymes: mechanisms of catalytic processes and inhibition. *Drug Resist. Update.* **4**: 106 –17.

Babini G S and Livermore D M (2000): Antimicrobial resistance among *Klebsiellae spp.* collected from intensive care units in Southern and Western Europe in 1997-1998. *J. Antimicrob. Chemother.* **45**:183-89.

- Bal M, Kumar A and Gould I M (2010):** Antibiotic heterogeneity: from concept to practice. *Annals of the New York Academy of Sciences, Antimicrobial Therapeutics Reviews* .**1213**: 81–91.
- Barber M and Rozwadowska-Dowzenko M (1948):** Infection by penicillin resistant *staphylococci*. *Lancet*. **4**: 252-641.
- Bayston R, Ashraf W and Smith T (2007):** "Triclosan resistance in methicillin-resistant *Staphylococcus aureus* expressed as small colony variants: a novel mode of evasion of susceptibility to antiseptics". *J. Antimicrob. Chemother.* **59** (5): 848–53.
- Bedenic B, Randegger C C, Stobberingh E and Hachler H (2001):** Molecular epidemiology of extended-spectrum beta-lactamases from *Klebsiella pneumoniae* strains isolated in Zagreb, Croatia. *Eur. J. Clin. Microbiol. Infect. Dis.* **20**:505-8.
- Beesley T, Gascoyne N, Knott – Hunziker V, Petursson S, Waley S G, Jaurin B and Grundstrom T (1983):** The inhibition of class C beta – lactamases by boronic acids. *Biochem. J.* **209**: 229 –33.
- Bermudes H, Arpin C, Jude F, El-Harrif Z, Bebear C and Quentin C (1997):** Molecular epidemiology of an outbreak due to extended-spectrum beta-lactamase-producing enterobacteria in a French hospital. *Eur. J. Clin. Microbiol. Infect. Dis.* **16**:523-29.
- Birmingham M C, Rayner C R, Meagher A K, Flavin S M, Batts D H and Schentag J J (2003):** "Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program". *Clin. Infect. Dis.* **36** (2): 159–68.

Bisson G, Fishman N O, Patel J B, Edelstein P H and Lautenbach E (2002): Extended - spectrum beta – lactamase - producing *Escherichia coli* and *Klebsiellae species*: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. *Infect. Control Hosp. Epidemiol.* **23**:254-60.

Bissonnette L, Champetier S, Buisson J P and Roy P H (1991): Charaterization of the nonenzymatic chloramphenicol resistance (cmlA) ene of the In4 integron of Tn1696: similarity of the product to transmembrane transport proteins. *J. Bacteriol.* **173**: 4493 –502.

Black J A, Moland E S, and Thomson K S (2005): AmpC Disc Test for detection of plasmid-mediated AmpC B- lactamases in Enterobacteriaceae Lacking Chromosomal AmpC B- Lactamases. *Journal of clinical Microbiology*, July. **43**(7): 3110-13.

Bouadma L, Luyt C E and Tubach F (2010): Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial Group): a multicentre randomized controlled trial. *Lancet.* **375**: 463–74.

Boucher H W, Talbot G H and Bradley J S (2009): Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis.* **48**:1-12

Bradford P A (2001): Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin. Microbiol. Rev.* **14**: 933-51.

Bradford P A, Urban C, Mariano N, Projan S J, Rahal J J and Bush K (1997): Imipenem resistance in *Klebsiella pneumoniae* is associated

with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein. *Antimicrob Agents Chemother.* **41**: 563- 9.

Bradley S J, Wilson A L and Allen M C (1999): The control of hyperendemic glycopeptides-resistant *Enterococcus spp.* on a haematology unit by changing antibiotic usage. *J. Antimicrob. Chemother.* **43**: 261–6.

Branger C, Bruneau B, Lesimple A L, Bouvet P J, Berry P, Sevali-Garcia J and Lambert-Zechovsky N (1997): Epidemiological typing of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* isolates responsible for five outbreaks in a university hospital. *J. Hosp. Infect.* **36**:23-36.

Bratu S, Tolaney P and Karumudi U (2005): Carbapenemase-producing *Klebsiella pneumoniae* in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. *J Antimicrob Chemother.* **56**:128-32.

Brenwald N P, Jevons G, Andrews J, Anq L and Fraise A P (2005): Disc methods for detecting AmpC β -lactamase – producing clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae*. *J. Antimicrob. Chemother.* **56** : 600 – 601.

Broskey J, Coleman K and Gwynn M N (2000): Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of *Streptococcus pneumoniae*. *J Antimicrob Chemother.* **45** (suppl. 1): 95 -9.

Brown D F, Andrews J, King A and MacGowan A P (2000): Detection of extended-spectrum beta-lactamases with Etest and double-disc potentiation methods. *J. Antimicrob. Chemother.* **46**:327-8.

Bruno-Murtha L A, Bruschi J and Bor D (2005): A pilot study of antibiotic cycling in the community hospital setting. *Infect. Control Hosp. Epidemiol.* **26**: 81–87.

Bureau-Chalot F, Drieux L, Pierrat-Solans C, Forte D, de Champs C and Bajolet O (2004): Blood pressure cuffs as potential reservoirs of extended-spectrum beta-lactamase VEB-1-producing isolates of *Acinetobacter baumannii*. *J. Hosp. Infect.* **58**:91-92.

Bush K (1989): Classification of β -lactamases—group-2c, group-2d, group-2e, group-3, and group-4. *Antimicrob. Agents Chemother.* **33**:271-6.

Bush K (2001): New β -lactamases in Gram – negative bacteria: diversity and impact on the selection of antimicrobial therapy. *Clinical Infectious Diseases.* **32**: 1085 -89.

Bush K, Jacoby G A and Medeiros A A (1995): A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrob. Agents Chemother.* **39**:1211-33.

Cantarelli V V, Inamine E, Cristina T, Brodt Z, Secchi C, Cavalcante B C and Pereira F (2007): Utility of the Ceftazidime – Imipenem Antagonism Test (CIAT) to Detect and Confirm the Presence of Inducible Amp C Beta – Lactamases Among Enterobacteriaceae. *The Brazilian Journal of Infectious Diseases* .11 (2): 237 –9.

Canton R, Oliver A, Coque T M, Varela Mdel C, Perez-Diaz G C and Baquero F (2002): Epidemiology of extended-spectrum beta-

lactamase-producing *Enterobacter* isolates in a Spanish hospital during a 12-year period. J. Clin. Microbiol. **40**:1237-43.

Casewell M W and Phillips I (1981): Aspects of the plasmid-mediated antibiotic resistance and epidemiology of *Klebsiellae species*. Am. J. Med. **70**:459-62.

Castanheira M, Sader H S and Deshpande L M (2008): Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. **52**:570-3

CDC (1995): Centers for Disease Control and prevention. Recommendations for preventing spread of vancomycin resistance. Infect. Control Hosp. Epidemiol. **16**:105–13.

CDC (2000): Centers for Disease Control and prevention. *Staphylococcus aureus* with reduced susceptibility to vancomycin—Illinois, 1999. Morb. Mortal. Wkly. Rep. **48**: 1165–67.

CDC (2002): Centers for Disease Control and prevention. Campaign to prevent antimicrobial resistance in health care settings, why a campaign: Atlanta CDIC. Available from www.cdc.gov/drugsresistance/healthcare/problem.htm.

CDC (2005): Centers for Disease Control and prevention. Department of Health and Human Services. Laboratory Detection of Oxacillin /Methicillin-resistant *Staphylococcus aureus*. Available from: <http://www.cdc.gov/ncidod/hip/Lab/FactSheet/mrsa.htm>.

CDC (2008): Centers for Disease Control and prevention. Campaign to prevent antimicrobial resistance in health care setting. Available from: www.cdc.gov/drugresistance/healthcare/ha/slideset.htm.

CDC (2009): Centers for Disease Control and prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. *MMWR*. **58**:256-60.

CDC NNIS (2004): National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004. *Am J Infect Control* , October .**32**: 470-85.

Cetinkaya Y, Pamela F and Glen C M (2000): Vancomycin resistant *enterococci*. *Clin. Microbiol. Rev.* **13**(4): 686-707.

Chambers H F (2003): Solving *staphylococcal* resistance to beta-lactams. *Trends Microbiol.* **11**:145-8.

Chanawong A, M'Zali F H, Heritage J, Lulitanond A and Hawkey P M (2001): Discrimination of SHV beta-lactamase genes by restriction site insertion-PCR. *Antimicrob. Agents Chemother.* **45**:2110-14.

Chastre J, Wolff M and Fagon J Y (2003): Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. *Pneum A Trial Group. JAMA* .**290**: 2588–98.

Cheesbrough M (2004): District laboratory practice in tropical countries. Part 2. Cambridge University Press. Chapter 7: antimicrobial sensitivity testing. P: 136- 141.

- Cherkaoui A, Renzi G, Francois P and Schrenzel J (2007):*** Comparison of four chromogenic media for culture-based screening of methicillin-resistant *Staphylococcus aureus*. *J Med Microbiol.* **56**(4):500-3.
- Chlebicki M P and Kurup A (2008):*** Vancomycin-resistant *Enterococcus* : A Review From a Singapore Perspective. Singapore General Hospital, Department of Infectious Diseases. *Ann. Acad. Med. Singapore.* **37**:861-90.
- Chopra I and Roberts M (2001):*** Tetracycline antibiotics: mode of action, applications molecular biology, and epidemiology of bacterial resistance. *Microbiol. Mol. Biol. Rev.* **65**: 232 –60.
- Clark N C, Cooksey R C, Hill B C, Swenson J M and Tenover F C (1993):*** Characterization of glycopeptide-resistant *enterococci* from US hospitals. *Antimicrob. Agents Chemother.* **37**:2311–17.
- CLSI (2006):*** Clinical and Laboratory standards institute: Performance standards for antimicrobial susceptibility testing, 16th informational supplements. CLSI Document M2-A9, Wayne PA.
- Cosgrove S E, Kaye K S, Eliopoulos G M and Carmeli Y (2002):*** health and economic outcomes of the emergences of third – generation cephalosporin resistance in *Enterobacter* species. *Arch. Intern. Med.* **162**: 185-90.
- Cotton M F, Wasserman E, Pieper C H, Theron D C, Van Tubbergh D, Campbell G, Fang F C and Barnes J (2000):*** Invasive disease due to extended spectrum beta-lactamase-producing *Klebsiella pneumoniae* in a neonatal unit: the possible role of cockroaches. *J. Hosp. Infect.* **44**:13-17.

- Coudron P E (2005):** Inhibitor – based methods for detection of plasmid – mediated Amp C β - lactamases in *Klebsiellae spp.*, *Escherichia coli*, and *Proteus mirabilis*. J. Clin. Microbiol. **43**: 4163 –7.
- Dahms R A, Johnson E M, Statz C L, Lee J T, Dunn D L and Beilman G J (1998):** Third generation cephalosporins and vancomycin as risk factors for postoperative vancomycin-resistant *Enterococcus* infection. Arch. Surg. **133**:1343–6.
- Davis S L, McKinnon P S and Hall L M (2007):** Daptomycin versus Vancomycin for Complicated Skin and Skin Structure Infections: Clinical and Economic Outcomes. Pharmacotherapy. **27**(12):1611–18. Available from: www.pharmacotherapy.org/avptoc.html
- Deresinski S (2005):** Methicillin- resistant *staphylococcus aureus*: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. **40**: 562-73
- DiazGranados C A, Zimmer S M, Klein M and Jernigan J A (2005):** Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible *enterococcal* bloodstream infections: a meta-analysis. Clin Infect Dis. **41**:327–33.
- Diekema D J, BootsMiller B J, Vaughn T E, Woolson R F, Yankey J W and Ernst E J (2004):** Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis. **38**:78–85.
- Donskey C J, Chowdhry T K, Hecker M T, Hoyer C K, Hanrahan J A, and Hujer A M (2000):** Effect of antibiotic therapy on the density of vancomycin resistant *enterococci* in the stool of colonized patients. N Engl J Med. **343**:1925-32.

- Drancourt M, Bollet C, Carta A, and Rousselier P (2001):** Phylogenetic analyses of *Klebsiellae species* delineate *Klebsiellae* and *Raoultella* gen. nov., with description of *Raoultella ornithinolytica* comb. nov., *Raoultella terrigena* comb. nov. and *Raoultella planticola* comb. nov. Int. J. Syst. Evol. Microbiol. **51**:925-32.
- Dunne M W Jr and Hardin D J (2005):** Use of Several Inducer and Substrate Antibiotic Combinations in a Disc Approximation Assay Format to Screen for AmpC Induction in Patient Isolates of *Pseudomonas aeruginosa*, *Enterobacter spp.*, *Citrobacter spp.*, and *Serratia spp.* Journal of clinical microbiology, Dec. **43**(12): 5945 –9
- Dutka-Malen S, Evers S and Courvalin P (1995):** Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant *enterococci* by PCR. J. Clin. Microbiol. **33**:24–27.
- Edmond M B, Ober J F, Weinbaum D L, Pfaller M A, Hwang T, Sanford M D and Wenzel R P (1995):** Vancomycin-resistant *Enterococcus faecium* bacteremia: risk factors for infection. Clin. Infect. Dis. **20**:1126–33.
- Eisen D, Russell E G, Tymms M, Roper E J, Grayson M J and Turnidge J (1995):** Random amplified polymorphic DNA and plasmid analyses used in investigation of an outbreak of multiresistant *Klebsiella pneumoniae*. J. Clin. Microbiol. **33**:713-17.
- El Kholy A, Baseem H, Hall G S, Procop G W and Longworth D L (2003):** Antimicrobial resistance in Cairo, Egypt 1999–2000: a survey of five hospitals. The British Society for Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy. **51**: 625–30.

Ericsson H and Sherris J C (1971): Antibiotic sensitivity testing. Report of an international collaborative study. *Acta Pathologies et Microbiologica Scandinavica Sect. B.* **217**(Suppl. 217:1+):1-90.

Evelina T and Maria A C (2008): Vancomycin-resistant *enterococci* (VRE) transmission and control. *International Journal of Antimicrobial Agents.***31**:99–106.

Faiers M, George R, Jolly J and Wheat P (1991): Multipoint Methods in the Clinical Laboratory. British Society for Microbial Technology. Public Health Laboratory Service, a hand book, London. Available from: www.worldcat.org/.../multipoint-methods-in-the-clinical-laboratory/.../26351375

Farrell D J and Jenkins S G (2004): Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among *Streptococcus pneumoniae* isolates collected from patients with respiratory tract infections: PROTEKT US 2001 – 2002. *J Antimicrob Chemother.* **54** (Suppl. 1: i):17 – 22.

Felmingham D and Brown D F J (2001): Instrumentation in antimicrobial susceptibility testing. *Journal of Antimicrobial Chemotherapy.***48** (1): 81-85.

Ferraro M J and Jorgensen J H (1999): Susceptibility testing instrumentation and computerized expert systems for data analysis and interpretation. American Society for Microbiology, Washington, DC .*Manual of Clinical Microbiology*, 7th edn, p. 1593-600. .

Fiett J, Palucha A, Miaczynska B, Stankiewicz M, Przondo-Mordarska H, Hryniewicz W and Gniadkowski M (2000): A novel complex mutant beta-lactamase, TEM-68, identified in a *Klebsiella*

- pneumoniae* isolate from an outbreak of extended-spectrum beta-lactamase-producing *klebsiellae*. Antimicrob. Agents Chemother. **44**:1499-505.
- Frainow H, Knob C, Herrero I and Patel R (2005):** Putative VanRS-like two component regulatory system associated with the inducible glycopeptide resistance cluster of *Paenibacillus popilliae*. Antimicrob. Agents Chemother. **49**:2625–33.
- French G L (1998):** Enterococci and vancomycin resistance. Clin Infect Dis. **27**(suppl. 1):75-83.
- French G L, Shannon K P and Simmons N (1996):** Hospital outbreak of *Klebsiella pneumoniae* resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase. J. Clin. Microbiol. **34**:358-63.
- Gaillot O, Maruejous C, Abachin E, Lecuru F, Arlet G, Simonet M and Berche P (1998):** Nosocomial outbreak of *Klebsiella pneumoniae* producing SHV-5 extended-spectrum beta-lactamase, originating from a contaminated ultrasonography coupling gel. J. Clin. Microbiol. **36**:1357-60.
- Garner J S, Jarvis W R, Emori T G, Horan T C and Hughes J M (1996):** CDC Definitions for nosocomial infections. APIC infection Control and Applied Epidemiology: Principles and Practice. Olmsted RN, ed. St. Louis: Mosby. p. A1-A20.
- Gaynes R and Edwards J R (2005):** Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. **41**:848-54.

- Gaynes R P and Horan T C (2005):** Surveillance of nosocomial infections: Hospital Epidemiology and Infection Control. Mayhall CG, ed. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; p. 1285-318.
- Gazouli M, Kaufmann M E and Tzelepi E (1997):** Study of an outbreak of cefoxitin-resistant *Klebsiella pneumoniae* in a general hospital. J Clin Microbiol. **35** (2): 508-510.
- Gerding D N, Larson T A and Hughes R A (1991):** Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob. Agents Chemother. **35**: 1284–90.
- Gill V J, Fedorko D P and Witebsky F G (2005):** The clinician and the Microbiology Laboratory: Principles and Practice of Infectious Diseases. International journal of infection control. 6th ed. Philadelphia: Elsevier; P.230-41
- Glupczynski Y, Berhin C, Bauraing C and Bogaerts P (2007):** Evaluation of a new selective chromogenic agar medium for detection of extended-spectrum β -lactamase-producing Enterobacteriaceae. J. Clin. Microbiol. **45**:501-505.
- Gottlieb T and Wolfson C (2000):** Comparison of the MICs of cefepime for extended-spectrum beta-lactamase-producing and non-extended-spectrum beta-lactamase-producing strains of *Enterobacter cloacae*. J. Antimicrob. Chemother. **46**:330-1.
- Gould I M (1999):** Review of the role of antibiotic policies in the control of antibiotic resistance. J. Antimicrob. chemother. **43**(4):459-65.
- Gould I M (2008):** The two Alexanders (Gordon and Ogston): Aberdeen's early contribution to the understanding of infection control. Int J. Antimicrob Agents. **32**: 467.

- Green M and Barbadora K (1998):** Recovery of ceftazidime-resistant *Klebsiella pneumoniae* from pediatric liver and intestinal transplant recipients. *Pediatr. Transplant.* **2**:224-30.
- Griffith R S (1981):** "Introduction to vancomycin". *Rev Infect Dis.* **3**(suppl. 2): S 200-S 204.
- Gupta A, Della-Latta P, Todd B, San Gabriel P, Haas J, Wu F, Rubenstein D and Saiman L (2004):** Outbreak of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in a neonatal intensive care unit linked to artificial nails. *Infect. Control Hosp. Epidemiol.* **25**:210-15.
- Gurran C, Holliday M G, Perry J D, Ford M, Morgan S and Orr K E (2002):** A novel selective medium for the detection of methicillin-resistant *Staphylococcus aureus* enabling result reporting in under 24 h. *J. Hosp. Infect.* **52**:148-51.
- Haddad-Prats L, Nguyen and Pitie-Salpetiere C H U (1999):** Evaluation of the OSIRIS video reader system for interpretation of disc diffusion susceptibility tests. *Clinical Microbiology and Infection.* **5**(Suppl. 3):92.
- Hanson N D (2003):** AmpC β -lactamases: what do we need to know for the future? *Journal of Antimicrobial Chemotherapy.* **52**: 2-4.
- Hanson N D and Sanders CC (1999):** Regulation of inducible AmpC β -lactamase expression among Enterobacteriaceae. *Current Pharmaceutical Design.* **5**: 881–94.
- Harris A D, Nemoy L, Johnson J A, Martin-Carnahan A, Smith D L, Standiford H and Perencevich E N (2004):** Co-carriage rates of

vancomycin-resistant *Enterococcus* and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance program. *Infect. Control Hosp. Epidemiol.* **25**:105-8.

Hemalatha V, Padma M, Sekar U, Vinodh T M and Arunkumar A S (2007):

Detection of AmpC beta lactamases production in *Escherichia coli* & *Klebsiellae* by an inhibitor based method. *Indian J Med Res*, September. **126**: 220 –3.

Héritier C, Poirel L, Aubert D and Nordmann P (2003):

Genetic and functional analysis of the chromosome-encoded carbapenem-hydrolyzing oxacillinase OXA-40 of *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* **47**:268-73.

Hibbert-Rogers L C, Heritage J, Gascoyne-Binzi D M, Hawkey P M, Todd

N, Lewis I J and Bailey C (1995): Molecular epidemiology of ceftazidime resistant Enterobacteriaceae from patients on a paediatric oncology ward. *J. Antimicrob. Chemother.* **36**:65-82.

Hidron A I, Edwards J R and Patel J (2008):

Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. NHSN annual update. *Infect Control Hosp Epidemiol.* **29**: 996 – 1011.

Hiramatsu K, Hanaki H and Ino T (1997):

Methicillin- resistant *Staphylococcus aureus* clinical strains with reduced vancomycin susceptibility. *J Antimicrob Chemother.* **40**:135-6.

Ho P L, Chow K H, Yuen K Y, Ng W S and Chau P Y (1998): Comparison of a novel, inhibitor-potentiated disc-diffusion test with other methods for the detection of extended-spectrum beta-lactamases in *Escherichia coli* and *Klebsiella pneumoniae*. J. Antimicrob.Chemother. **42**:49-54.

Hobson R P, MacKenzie F M and Gould I M (1996): An outbreak of multiply-resistant *Klebsiella pneumoniae* in the Grampian region of Scotland. J. Hosp. Infect. **33**:249-62.

Hooper D C (1998): Clinical applications of quinolones. Biochem. Biophys. Acta. **1400**: 45 – 61.

Huang Te-Din, Bogaerts P, Berhin C, Guisset A and Glupczynski Y (2010): Evaluation of Brilliance ESBL Agar, a Novel Chromogenic Medium for Detection of Extended – Spectrum – Beta - Lactamase Producing Enterobacteriaceae .J Clin Microbiol. June. **48**(6): 2091-6.

Huovinen P, Huovinen S and Jacoby G A (1988): Sequence of PSE-2 beta – lactamase. Antimicrob. Agents Chemother. **32**:134 –6.

Iannelli F, Santagat M, Doquier J D , Cassone M, Oggioni M R and Rossolini G (2004): Type M resistance to macrolides in streptococci is not due to the *mef* (A) gene, but to *mat* (A) encoding and ATP – dependent efflux pump [Abstract C1-1188]. In: Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington; Oct 30 – Nov 2.

IFIC (2007): International Federation of infection control: Basic concepts of infection control, Principles of antibiotic policies, chapter 7; P. 57-64. Available from: www.theifc.org/basic_concepts/index.htm -.

Jacoby G, Han P and Tran J. (1997): Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant Gram-negative clinical pathogens. *Antimicrob Agents Chemother.* **41**: 1830-1.

Janknegt R (1997): "The treatment of staphylococcal infections with special reference to pharmacokinetic, pharmacodynamic, and pharmacoeconomic considerations". *Pharmacy world & science: PWS.* **19** (3): 133–41.

Jarlier V, Nicolas M H, Fournier G and Philippon A (1988): Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. *Rev. Infect. Dis.* **10**:867-78.

Jarvis W R (2007): The Lowbury Lecture: the United States approach to strategies in the battle against healthcare-associated infections, 2006: transitioning from benchmarking to zero tolerance and clinician accountability. *J Hosp Infect.* **65** (Suppl. 2):3-9.

Jaurin B and Grundstrom T (1981): AmpC cephalosporinase of *Escherichia coli* K – 12 has a different evolutionary origin from that of b – lactamases of the penicillianse type. *Proc. Natl. Acad. Sci. USA.* **78**: 4897 – 4901.

Jeannot K, Sobel M L, Garch F E L, Poole K and Plesiat P (2005): Induction of the MexXY efflux pump in *Pseudomonas aeruginosa* is dependent on drug – ribosome interaction. *J. Bacteriol.* **187**: 5341-6.

Jeong S H, Song W, Kim J S, Kim H S and Lee K M (2009): Broth microdilution method to detect extended-spectrum beta-lactamases and AmpC beta - lactamases in Enterobacteriaceae isolates by use of

clavulanic acid and boronic acid as inhibitors. *J. Clin. Microbiol.* **47**:3409-12.

Jett B, Free L and Sahn D F (1996): Factors influencing the Vitek Gram-Positive Susceptibility system's detection of vanB-encoded vancomycin resistance among *enterococci*. *J. Clin. Microbiol.* **34**:701–6.

Kahne D, Leimkuhler C, Wei L and Christopher W (2005): Glycopeptide and Lipoglycopeptide Antibiotics. *Chem. Rev.* **105**: 425- 48.

Kainer M A, Devasia R A, Jones T F, Simmons B P, Melton K, Chow S (2007): Response to emerging infection leading to outbreak of linezolid- resistant *enterococci*. *Emerg Infect Dis.* **13**:1024–30.

Karabinis A, Paramythiotou E, Mylona-Petropoulou D, Kalogeromitros A, Katsarelis N, Kontopidou F, Poularas I, and Malamou-Lada H (2004): Colistin for *Klebsiella pneumoniae*-associated sepsis. *Clin. Infect. Dis.* **38**:E7-E9.

Kasbekar N (2006): "Tigecycline: a new glycylycylcline antimicrobial agent." *Am J. Health Syst. Pharm.* **63** (13): 1235–43.

Katayama Y, Ito T and Hiramatsu K (2000): A new class of genetic element, *Staphylococcus* cassette chromosome mec, encodes methicillin resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **44**:1549-55.

Kelly T, Killian S B, Knapp C C, Anderson P and Pereira A (1998): Evaluation of the new imaging system Accuzone for disc diffusion susceptibility testing and data management. In Abstracts of

the Ninety-Eighth General Meeting of the American Society for Microbiology, Atlanta, GA. C-475: p. 210.

Kenneth S and Thomson (2010): Extended-Spectrum- β -Lactamase, AmpC, and Carbapenemase. Issues J Clin Microbiol. April. **48**(4): 1019–25.

Kim J and Lee H J (2000): Rapid discriminatory detection of genes coding for SHV beta-lactamases by ligase chain reaction. Antimicrob. Agents Chemother. **44**:1860-4.

Kochar S, Sheard T and Sharma R (2009): Success of an infection control program to reduce the spread of carbapenem-resistant *Klebsiella pneumoniae*. Infect Control Hosp Epidemiol. **30**:447-52.

Kohner P C, Patel R, Uhl J R, Garin K M, Hopkins M K, Wegener L T and Cockerill F R (1997): Comparison of Agar Dilution, Broth Microdilution, E-Test, Disc Diffusion, and Automated Vitek Methods for Testing Susceptibilities of *Enterococcus spp.* to Vancomycin. Journal of Clinical Microbiology. **35**(12): 3258–63.

Konig B, Parkner A and Konig W (1999): Reliable detection of *van A*, *vanB*, *vanC1* and *vanC2* vancomycin resistance by automated susceptibility testing. Clinical Microbiology and Infection. **5** (Suppl. 3): 92.

Korgenski E K and Daly J A (1998): Evaluation of the BIOMIC video reader system for determining interpretive categories of isolates on the basis of disc diffusion susceptibility results. Journal of Clinical Microbiology. **36**:302-4.

- Kucers A, Crow S, Grayson M L and Hoy J (1997):** The use of antibiotics: A clinical review of antibacterial, antifungal, and antiviral drugs. 5th ed. Oxford: Butterworth Heinemann, 452 – 457.
- Kumar R, Indira K and Rizvi A (2008):** Antibiotic prescribing practices in primary and secondary health care facilities in Uttar Pradesh, India. J. Clin. Pharm. Ther. **33**: 625–34.
- Lally R T, Ederer M N and Woolfrey B F (1985):** Evaluation of mannitol salt agar with oxacillin as a screening medium for methicillin-resistant *Staphylococcus aureus*. J. Clin. Microbiol. **22**: 501-4.
- Laupland K B, Zygun D A, Davies H D, Church D L, Louie T J and Doig C J (2002):** Incidence and risk factors for acquiring nosocomial urinary tract infection in the critically ill. J Crit Care. **17**(1):50-7.
- Leclercq R, Derlot E, Duval J and Courvalin P (1988):** Plasmid-mediated resistance to vancomycin and teicoplanin in *Enterococcus faecium*. N. Engl. J. Med. **319**:157–61.
- Lee K, Chong Y and Shin H B (2001):** Modified Hodge and EDTA-disc synergy tests to screen metallo-beta-lactamase-producing strains of *Pseudomonas* and *Acinetobacter* species. Clin Microbiol Infect. **7**: 88-91.
- Lee K, Lee W G, Uh Y, Ha G Y, Cho J and Chong Y (2003):** VIM- and IMP-type metallo-β-lactamase-producing *Pseudomonas* spp. and *Acinetobacter* spp. in Korean hospitals. Emerg. Infect. Dis. **9**:868-71.
- Levison M E, Mailapur Y V, Pradhan S K, Jacoby J A, Adams P, Emery C L, May P L and Pitsakis P G (2002):** Regional occurrence

- of plasmid-mediated SHV-7, an extended-spectrum beta-lactamase, in *Enterobacter cloacae* in Philadelphia Teaching Hospitals. Clin. Infect. Dis. **35**:1551-4.
- Li J, Nation R L and Turnidge JD (2006):** Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet. Infect Dis. **6**: 589 - 601.
- Lima – Bittencourt C I, Cursino L, Concalves – Dornelas H and Pontes D S (2007):** Multiple antimicrobial resistance in Enterobacteriaceae isolates from pristine freshwater. Genet. Mol. Res. **6** (3): 510 –21.
- "Lincosamides, Oxazolidinones, and Streptogramins" (2005):** Clindamycin. Merck Manual of Diagnosis and Therapy. Available from: <http://www.merck.com/mmpe/print/sec14/ch170/ch170g.html>.
- Linden P K, Kusne S, Coley K, Fontes P, Kramer D J and Paterson D (2003):** Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant *Pseudomonas aeruginosa*. Clin. Infect. Dis. **37**:E154-E160.
- Livermore D M (1995):** Beta-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. **8**:557-84.
- Livermore D, Winstanley T G and Shannon K P (2001):** Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. Journal of Antimicrobial Chemotherapy. **48**(Suppl. 1): 59-64.
- Livermore D M, Warner M and Mushtaq S (2007):** Evaluation of the chromogenic Cica-b-test for detecting extended-spectrum, AmpC and metallo-b-lactamases. J Antimicrob Chemother. **60**: 1375–90.

- MacKenzie F M, Miller C A and Gould I M (2002):** Comparison of screening methods for TEM- and SHV-derived extended-spectrum beta-lactamase detection. *Clin. Microbiol. Infect.* **8**:715-24.
- Manzella J P (2001):** "Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections." *Am. Fam. Physician.* **64**(11):1863-67.
- Marco J A, Naranjo O R, Felipe R, Buenaventura B and Jesus S S (2008):** Mechanisms of Resistance by Gram-Positive Bacteria (*Streptococci* and *Enterococci*). *Antimicrobial Resistance and Implications for the Twenty-First Century.* Chapter 1. P: 25-28.
- Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I and Gregorakos L (2003):** Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. *Crit. Care.* **7**:R78-R83.
- Martinez – Martinez L, Pascual A and Jacoby G A (1998):** Quinolone resistance from a transferable plasmid. *Lancet.* **351**(issue 9105): 797-9.
- Maseda H, Yoneyama H and Nakae T (2000):** Assignment of the substrate – selective subunits of the MexEF –OprN multidrug efflux pump of *pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* **44**: 658 – 64.
- Massidda O, Rossolini G M, and Satta G (1991):** The *Aeromonas hydrophila* *cphA* gene: molecular heterogeneity among class B metallo- β -lactamases. *J. Bacteriol.* **173**:4611-17.
- Mast (2010):** AmpC + ESBL Detection set-Mastgroup Ltd: D68C Pack size: 4 X 50 CARTRIDGES Product status. Available from www.mastgrp.com/catalogue_products_fulldetails.asp?

Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman M D, Wakiguchi H, Sugihara S, Sugiura T, Koda S, Muraoka A and Imai S (2003): "Experimental protection of mice against lethal *Staphylococcus aureus* infection by novel bacteriophage phi MR11". *J. Infect. Dis.* **187** (4): 613–24.

Maus C E, Plikaytis B B and Shinnick T M (2005): Molecular analysis of cross – resistance to capreomycin, kanamycin, amikacin, and viomycin in *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **49**: 3192–7.

McDonnell Norms Group (2008): Antibiotic overuse: the influence of social norms. *J. Am. Coll. Surg.* **207**: 265–75.

McGowan J E and Tenover F C (1997): Control of antimicrobial resistance in the health care system. *Infectious Disease Clinics of North America.* **11**: 297 – 311.

McNulty C A and Francis N A (2010): Optimizing antibiotic prescribing in primary care settings in the UK: findings of a BSAC multi-disciplinary workshop 2009. *J. Antimicrob. Chemother.* **65**: 2278–84.

Medeiros A A and Crellin J (2000): Evaluation of the SIRSCAN automated zone reader in a clinical microbiology laboratory. *Journal of Clinical Microbiology.* **38**: 1688-93.

Meyers B R, Kaplan K and Weinstein L (1969): "Microbiological and pharmacological behavior of 7-chlorolincomycin". *Appl. Microbiol.* **17** (5): 653–7.

- Migliavacca R, Docquier J D, Mugnaioli C, Amicosante G, Daturi R, Lee K W, Rossolini G M and Pagani L (2002):** Simple microdilution test for detection of metallo- β -lactamase production in *Pseudomonas aeruginosa*. J. Clin. Microbiol. **40**:4388-90.
- Mingeot – Leclercq M P, Glupczynski Y and Tulkens P M (1999):** Aminoglycosides: Activity and Resistance. Antimicrobial Agents and Chemotherapy. **43**: 727 – 37.
- Modric J (2008):** MRSA Superbug Types: CA-MRSA, HA-MRSA .Received from: <http://www.healthhype.com/mrsa-superbug.html>
- Moland E S, Hanson N D, Black J A, Hossain A, Song W and Thomson KS (2006):** Prevalence of newer β -lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. J. Clin. Microbiol. **44**:3318-24.
- Moland E S, Kim S Y, Hong S G and Thomson K S (2008) :** Newer beta-lactamases: clinical and laboratory implications, part I. Clin. Microbiol. Newsl. **30**:71-77
- Mongkolrattanothai K, Boyle S, Kahana M D and Daum R S (2003):** Severe *Staphylococcus aureus* infections caused by clonally related community-associated methicillin-susceptible and methicillin-resistant isolates. Clin. Infect. Dis. **37** (8): 1050–8.
- Monsef A and Eghbalian F (2010):** Antibiotic sensitivity pattern of common bacterial pathogens in NICU and neonatal ward in Hamedan province of Iran. Health. **2**(6): 625-9.
- Montecalvo M A, deLancestre H, Carraher M, Gedris C, Chung M, Horn KV and Wormser G P (1995):** Natural history of colonization with

vancomycin-resistant *Enterococcus faecium*. Infect. Control Hosp. Epidemiol. 16: 680–685.

Montgomery J, Nakos J and Gurtler V (2008): Comparison of phenotypic tests for detection of plasmid – mediated AmpC β – lactamases. ESCMID 18th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona, Spain, 19 – 22 April.

Murray B E (1998): Diversity among multidrug-resistant *enterococci*. Emerg. Infect. Dis. 4:37-47.

Murray I A and Shaw W V (1997): O – Acetyltransferases for chloramphenicol and other natural products. Antimicrob. Agents Chemother. 41: 1-6.

M'Zali F H, Chanawong A, Kerr K G, Birkenhead D and Hawkey P M (2000): Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: comparison of the MAST DD test, the double disc and the Etest ESBL. J. Antimicrob. Chemother. 45:881-5.

Nakatomi Y and Sugiyama J (1998): MRSA Latex Test for Pbp2'. Microbiol. Immunol.42:739-43.

Nasim K, Elsayed S, Pitout J D D, Conly J, Church D L and Gregson D B (2004): New Method for laboratory Detection of AmpC β -Lactamases in *Escherichia coli* and *Klebsiella pneumoniae*. Journal of Clinical Microbiology, Oct. 42(10): 4799 – 4802.

NCCLS (1999): National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. NCCLS approved standard M100 – S9. Wayne, PA.

NCCLS (2000): National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard. M7-A4. Wayne, Pennsylvania.

NCCLS (2003): National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard, M7-A6. Wayne, Pennsylvania.

NCCLS (2003): National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disc susceptibility tests. Approved standard, M2 – A8. Wayne, PA.

NCCLS (2005): National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing; 15th informational supplement (M100-S15). Wayne, PA.

NNIS (2002): National Nosocomial Infections Surveillance: System Report, data summary from January 1992 to June 2002, Am. J. Infect. Control. **30**:458-75.

Navon-Venezia S, Leavitt A and Schwaber M J (2009): First report on a hyperepidemic clone of KPC-3-producing *Klebsiella pneumoniae* in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother. **53**: 818 –20

Neuwirth C, Madec S, Siebor E, Pechinot A, Duez J M, Pruneaux M, Fouchereau-Peron M, Kazmierczak A and Labia R (2001): TEM-89 beta-lactamase produced by a *Proteus mirabilis* clinical isolate:

new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3. *Antimicrob. Agents Chemother.* **45**:3591-4.

Nordmann P and Poirel L (2002): Emerging carbapenemases in Gram-negative aerobes. *Clin. Microbiol. Infect.* **8**:321-31.

Nordmann P, Cuzon G and Naas T (2009): The real threat of *Klebsiella pneumoniae* carbapenemase-producing bacteria. *Lancet. Infect Dis.* **9**:228-36.

Novak S M, Hindler J and Bruckner D A (1993): Reliability of two novel methods, Alarm and E test, for detection of methicillin-resistant *Staphylococcus aureus*. *Journal of Clinical Microbiology* **31**: 3056-7.

Nsira S B, Dupuis M and Leclercq R (2006): Evaluation of MRSA Select, a new chromogenic medium for the detection of nasal carriage of methicillin-resistant *Staphylococcus aureus*. *Int. J. of Antimicrob. Agents.* **27**:561-4.

Okuma K, Iwakawa K and Turnidge J (2002): Dissemination of new methicillin-resistant *Staphylococcus aureus* clones in the community". *J Clin Microbiol.* **40** (11): 4289–94.

Parfitt T (2005): "Georgia: an unlikely stronghold for bacteriophage therapy". *Lancet.* **365** (9478): 2166–7.

Patel R (2003): Clinical impact of vancomycin-resistant *enterococci*. *Journal of Antimicrobial Chemotherapy.* **51**(Suppl. S3): iii13–iii21.

Patel G, Huprikar S and Factor S H (2008): Outcomes of carbapenem-resistant *Klebsiella pneumoniae* infection and the impact of

antimicrobial and adjunctive therapies. *Infect. Control Hosp. Epidemiol.* **29**:1099-1106.

Paterson D (2006): Resistance in gram-negative bacteria: Enterobacteriaceae. *American Journal of Infection Control.* **34** (Issue 5):S20 – S28.

Paterson D L (2009): Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β -lactamases (ESBLs). *Clinical Microbiology and Infection*, September . **6**(Issue 9): 460–3.

Paterson D L and Yu V L (1999): Extended – spectrum - β - Lactamases. A call for improved detection and control. *Clin. Infect Dis.* **29**: 1419-22.

Paterson D L, Von Ko W and Gottberg A (1998): In vitro susceptibility and clinical outcome of bacteremia due to extended-spectrum beta-lactamase producing *Klebsiella pneumoniae*. *Clin.Infect Dis.* **27**: 956

Paterson D L, Mulazimoglu L and Casellas J M (2000): Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in *Klebsiella pneumoniae* isolates producing bacteremia. *Clin. Infect. Dis.* **30**: 473- 8.

Peleg A Y and Hooper D C (2010): Hospital-Acquired Infections Due to Gram-Negative Bacteria. *N Engl J. Med.* **362**:1804-13.

Perry J D, Davies A, Butterworth L A, Hopley A L J, Nicholson A and Gould F K (2004): Development and evaluation of a chromogenic agar medium for methicillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.* **42** (10):4519-23.

- Peterson L R (2008):** Antibiotic policy and prescribing strategies for therapy of extended - spectrum beta – lactamase - producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin. Microbiol. Infect. **14**(Suppl. 1):181-4.
- Pfizer (2008).** "ZYVOX (linezolid) Label Information" (PDF). Available from :<http://www.fda.gov/cder/foi/label/2008/021130s016,021131s013,021132s014lbl.pdf>.
- Philippon A and Jacoby G A (2002):** Plasmid determined AmpC –type B-lactamases. Antimicrob. Agents Chemother. **46**: 1-11.
- Piddock L J (1999):** Mechanisms of fluroquinolone resistance : an update, 1994 -1998. Drugs.**58**: 11-18.
- Pillay T, Pillay D G, Adhikari M and Sturm A W (1998):** Piperacillin/tazobactam in the treatment of *Klebsiella pneumoniae* infections in neonates. Am J. Perinatol .**15**: 47 - 51.
- Pirisi A (2000):** "Phage therapy—advantages over antibiotics?". Lancet. **356**(9239): 1418.
- Podschun R and Ullmann U (1998):** *Klebsiellae spp.* as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin. Microbiol. Rev. **11**:589-603.
- Poirel L, Weldhagen GF, Naas T, De Champs G, Dove M G, and Nordmann P (2001):** GES-2, a class A β -lactamase from *Pseudomonas aeruginosa* with increased hydrolysis of imipenem. Antimicrob. Agents Chemother. **45**:2598-2603.
- Poirel L, Heritier C and Nordmann P (2004):** Chromosome-encoded ambler class D β -lactamase of *Shewanella oneidensis* as a progenitor

of carbapenem-hydrolyzing oxacillinase. *Antimicrob. Agents Chemother.* **48**:348-51.

Poole K (2003): Overcoming multidrug resistance in gram –negative bacteria. *Current Opinion in Investigational Drugs.* **4**(2): 128- 39.

Pugh R J, Cooke R P and Dempsey G (2010): Short course antibiotic therapy for Gram-negative hospital-acquired pneumonia in the critically ill. *J. Hosp. Infect.* **74**: 337–43.

Queenan A M and Bush K (2007): Carbapenemases: the versatile beta-lactamases. *Clin. Microbiol Rev.* **20**:440-58.

Queenan A M, Foleno B, Gownley C, Wira E and Bush K (2004): Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella pneumoniae* clinical isolates tested by using National Committee for Clinical Laboratory Standards ESBL methodology. *J. Clin. Microbiol.* **42**:269-275.

Rahal J J (2006): Novel antibiotic combinations against infections with almost completely resistant *Pseudomonas aeruginosa* and *Acinetobacter species*. *Clin. Infect Dis.* **43**(suppl 2):S95-S99.

Randegger C C and Hachler H (2001): Real-time PCR and melting curve analysis for reliable and rapid detection of SHV extended-spectrum beta-lactamases. *Antimicrob. Agents Chemother.* **45**:1730-36.

Randrianirina F, Vaillant L, Ramarokoto C E, Rakotoarijaona A, Andriamanarivo M L, Razafimahandry H C and Randrianomenjanahary J (2010): Antimicrobial resistance in

pathogens causing nosocomial infections in surgery and intensive care wards in Antananarivo, Madagascar. *J Infect. Dev. Ctries.* **4**(2):074-082.

Rasmussen B A and Bush K (1997): Carbapenem-hydrolyzing β -lactamases. *Antimicrob. Agents Chemother.* **41**:223-32.

Rather P N (1998): Origins of aminoglycoside modifying enzymes. *Drug Resist. Update.* **1**: 285 –91.

Raymond D P, Pelletier S J and Crabtree T D (2001): Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. *Crit. Care Med.* **29**:1101–8.

Revathi G, Shannon K P, Stapleton P D, Jain B K and French G L (1998): An outbreak of extended-spectrum, beta-lactamase-producing *Salmonella senftenberg* in a burns ward. *J. Hosp. Infect.* **40**:295-302.

Rogues A M, Boulard G, Allery A, Arpin C, Quesnel C, Quentin C, Bebear C, Labadie J C and Gachie J P (2000): Thermometers as a vehicle for transmission of extended-spectrum-beta-lactamase producing *Klebsiella pneumoniae*. *J. Hosp. Infect.* **45**:76-7.

Ruzin A, Visalli M A, Keene D Y and Bradford P A (2005): Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* **49**: 1017 –22.

Safdar N and Maki D G (2002): The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant

- Staphylococcus aureus*, *Enterococcus*, gram-negative bacilli, *Clostridium difficile*, and *Candida*. Ann. Intern. Med. **136**:834-44.
- Sakazaki R, Tamura K, Kosako Y, and Yoshizaki E (1989):** *Klebsiella ornithinolytica* sp. nov., formerly known as ornithine-positive *Klebsiella oxytoca*. Curr. Microbiol. **18**:201-6.
- Sanches I S, Saravaiva Z C, Tendeiro T C, Serra J M, Dias D C and de Lencastre H (1998):** Extensive intra-hospital spread of a methicillin-resistant *Staphylococcus aureus* clone. Int. J. Infect. Dis. **3**:26–31.
- Sanchez – Pescador R, Brown J T, Roberts M and Urdea M S (1988):** Homology of the TetM with translational elongation factors: implications for potential modes of tetM-conferred tetracycline resistance. Nucleic acids Res. **16**:1218.
- Sanders C C, Barry A L, Washington J A, Shubert C, Moland E S, Traczewski M, Knapp C and Mulder R (1996):** Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test. J. Clin. Microbiol. **34**:2997-3001.
- Sanguinetti M, Posteraro B, Spanu T, Ciccaglione D, Romano L, Fiori B, Nicoletti G, Zanetti S and Fadda G (2003):** Characterization of clinical isolates of Enterobacteriaceae from Italy by the BD Phoenix extended-spectrum beta-lactamase detection method. J. Clin. Microbiol. **41**:1463-8.
- Satake S, Clark N, Rimland D, Nolte F S and Tenover F C (1997):** Detection of Vancomycin-Resistant *Enterococci* in Fecal Samples by PCR. J. Clin. Microbiol. **35**(9): 2325–30

- Schito G C (2006):** "The importance of the development of antibiotic resistance in *Staphylococcus aureus*". Clin. Microbiol. Infect. **12** (Suppl: 1): 3–8.
- Schooneveldt J M, Nimmo G R and Giffard P (1998):** Detection and characterisation of extended spectrum beta-lactamases in *Klebsiella pneumoniae* causing nosocomial infection. Pathology. **30**:164-8.
- Schulz J E and Sahn D F (1993):** Reliability of the E Test for Detection of Ampicillin, Vancomycin, and High-Level Aminoglycoside Resistance in *Enterococcus spp.* J. of Clin. Micro. **31**(12): 3336-9.
- Schvartzman J B and Stasiak A (2004):** A topological view of the replicon. EMBO reports. **5**(3): 256 –61
- Schwaber M J and Carmeli Y (2008):** Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA. **300**:2911-13.
- Schwalbe R S, Stapleton J T and Gilligan P H (1987):** Emergence of vancomycin resistance in *coagulase-negative staphylococci*. N Engl. J. Med. **316**:927-31.
- Schwarz, Kehrenberg C., Doublet B., and Cloeckert A (2004):** Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS. Microbiol. Rev. **28**: 519 –42.
- Scoulica E V, Neonakis I K, Gikas A I and Tselentis Y J (2004):** Spread of *bla*_{VIM-1}-producing *E. coli* in a university hospital in Greece. Genetic analysis of the integron carrying the *bla*_{VIM1} metallo-β-lactamase gene. Diagn. Microbiol. Infect.Dis.**48**:167-72.

- Segal-Maurer S, Mariano N, Qavi A, Urban C and Rahal J J (1999):** Successful treatment of ceftazidime-resistant *Klebsiella pneumoniae* ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Clin. Infect. Dis; **28**: 11348.
- Shahid M, Malik A and Agrawal M (2004):** Phenotypic detection of extended – spectrum and AmpC b – lactamases by a new spot – inoculation method and modified three – dimensional extract test : comparison with the conventional three – dimensional extract test. Journal of Antimicrobial Chemotherapy .**54**: 684 –7.
- Shales D M, Gerding D N, John J F, Craig W A, Bornstein D L, Duncan R A (1997):** Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infection Control and Hospital Epidemiology. **18**(4):275 – 91
- Shannon K, Fung K, Stapleton P, Anthony E Power and French G (1998):** A hospital outbreak of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* investigated by RAPD typing and analysis of the genetics and mechanisms of resistance. J. Hosp. Infect. **39**:291-300.
- Sharath S H, Noe R, Tania W, Nicole V, Robert S, Julia M, Kone K, John P, Roger T, Jeng-Pyng S, Glen O and Kevin J (2004):** Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive Bacteria. Antimicrobial agent and chemotherapy. **48**(8):3043–50.

- Shen, Winokur D P and Jones R N (2001):** Characterization of extended spectrum beta – lactamase – producing *Klebsiella pneumoniae* from Beijing, China. *Int. J. Antimicrob. Agents.* **18**: 185 –8.
- Shibata, N, Doi Y, Yamane K, Yagi T, Kurokawa H, Shibayama K, Kato H, Kai K, and Arakawa Y (2003):** PCR typing of genetic determinants for metallo- β -lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. *J. Clin. Microbiol.* **41**:5407-13.
- Shortridge V D, Doern G V, Brueggemann A B, Beyer J M and Flamm R K (1999):** Prevalence of macrolide resistance mechanisms in *streptococcus pneumoniae* isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994 – 1995. *Clin. Infect. Dis.*, **29**: 1186 -8.
- Showsh S A, DeBoever R H and Clewell D B (2001):** Vancomycin resistance plasmid in *Enterococcus faecalis* that encodes sensitivity to a sex pheromone also produced by *staphylococcus aureus*, *Antimicrob. Agents Chemother.* **45**: 2177- 8.
- Skov R, Smyth R, Larsen AR, Frimodt-Möller N and Kahlmeter G (2005):** Evaluation of cefoxitin 5 and 10 μ g discs for the detection of methicillin resistance in *staphylococci*. *J. Antimicrob. Chemother.* **55**:157-61.
- Slama G T (2008):** Gram – negative antibiotic resistance: there is a price to pay. *Critical Care.* **12** (suppl 4): S4
- Slatore C G (2004):** "Sulfonamide hypersensitivity". *Immunology and Allergy. Clinics of North America.* **24**(3): 477–90

Song W, Bae I K, Lee Y, Lee C, Lee S H and Jeong S H (2007): Detection of Extended – Spectrum β - Lactamases by Using Boronic Acid as an AmpC β -Lactamase inhibitor in Clinical Isolates of *Klebsiellae spp.* and *Escherichia coli*. Journal of clinical Microbiology, Apr. **45**(4): 1180 –4

Souli M, Galani I and Giamarellou H (2008): Emergence of extensively drug-resistant and pan drug-resistant Gram-negative bacilli in Europe. Euro Surveill. **13**(47):ii=19045.

Spanu T, Sanguinetti M, Tumbarello M, D'Inzeo T, Fiori B, Posteraro B, Santangelo R, Cauda R and Fadda G (2006): Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates. J. Clin. Microbiol.**44**:3257-62.

Spreitzer H (2007): Mechanism of action of tetracyclin antibiotics:"Neue Wirkstoffe - Incyclinid" (in German). Österreichische Apothekerzeitung **14**: 655.

Stein G E and Craig W A (2006): Tigecycline: a critical analysis. Clin. Infect. Dis. **43**: 518-24.

Sturenburg E, Lang M, Horstkotte M A, Laufs R and Mack D (2004): Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum beta-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria. J. Antimicrob. Chemother. **54**:870-5.

- Swaney S M, Aoki H, Ganoza M C and Shinabarger D L (1998):** The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. *Antimicrobial Agents and Chemotherapy*. **42**: 3251–5.
- Swenson J M, Clark N C, Ferraro M J, Sahm D F, Doern G, Pfaller M A, Reller L B, Weinstein M P, Zabransky R J and Tenover F C (1994):** Development of a standardized screening method for detection of vancomycin-resistant *enterococci*. *J. Clin. Microbiol.* **32**:1700–4.
- Szabo D, Filetoth Z, Szentandrassy J, Nemedi M, Toth E, Jeney C, Kispal G and Rozgonyi F (1999):** Molecular epidemiology of a cluster of cases due to *Klebsiella pneumoniae* producing SHV-5 extended-spectrum beta-lactamase in the premature intensive care unit of a Hungarian hospital. *J. Clin. Microbiol.* **37**:4167-9.
- Tait – Kamradt A, Davies T, Cronan M, Jacobs M R, Appelbaum P C and Sutcliffe J (2000):** Mutations in 23S rRNA and ribosomal protein L4 account for resistance in *pneumococcal* strains selected in vitro by macrolide passage. *Antimicrob Agents Chemother.* **44**: 2118 – 25.
- Takesue Y, Nakajima K, and Ichiki K (2010):** Impact of a hospital-wide programme of heterogeneous antibiotic use on the development of antibiotic-resistant Gram-negative bacteria. *J. Hosp. Infect.* **75**: 28–32.
- Tam V H, Schilling A N, Vo G, Kabbara S, Kwa A L, Wiederhold N P and Lewis R E (2005):** Pharmacodynamics of polymyxin B against *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* **49**: 3624–30.

Tenover F C, Tokars J, Swenson J, Paul S, Spitalny K and Jarvis W (1993): Ability of clinical laboratories to detect antimicrobial agent resistant *enterococci*. *J. Clin. Microbiol.* **31**:1695–9.

Then R L (1982): Mechanisms of resistance to trimethoprim, the sulphonamides, and trimethoprim – sulfamethoxazole. *Rev. Infect. Dis.* **4**: 261 –9.

Then R L and Angehrn P (1979): Low trimethoprim susceptibility of anaerobic bacteria due to insensitive dihydrofolate reductases. *Antimicrob. Agents Chemother.* **15**: 1 – 6.

Thomson K S (2001): Controversies about extended – spectrum and AmpC beta – lactamases. *Emerg. Infect. Dis.* **7**: 333 –6.

Thomson K S and Sanders C C (1992): Detection of extended – spectrum beta – lactamases in members of the family Enterobacteriaceae: comparison of the double – disc and three – dimensional tests. *Antimicrob. Agents Chemother.* **36**: 1877 –82.

Thomson K S, Cornish N E, Hong S G, Hemrick K, Herdt C and Moland E S (2007): Comparison of Phoenix and VITEK 2 extended-spectrum-beta-lactamase detection tests for analysis of *Escherichia coli* and *Klebsiellae* isolates with well-characterized beta-lactamases. *J. Clin. Microbiol.* **45**:2380-4.

Thornsberry C and McDougal L K (1983): Successful use of broth microdilution in susceptibility tests for methicillin-resistant (heteroresistant) staphylococci. *Journal of Clinical Microbiology.* **18**:1084-91.

- Toleman M A, Simm A M, Murphy T A, Gales A C, Biedenbach D J, Jones R N, and Walsh T R (2002):** Molecular characterization of SPM-1, a novel metallo- β -lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. *J. Antimicrob. Chemother.* **50**:673-9.
- Trekds (2011):** Trek diagnostic systems. Magellan Biosciences. The new energy in microbiology. Available from: www.trekds.com
- Tsakris A, Poulou A, Pournaras S, Voulgari E, Vrioni G, Themeli-Digalaki K, Petropoulou D and Sofianou D (2010):** A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. *J. Antimicrob. Chemother.* , Aug. **65**(8):1664-71.
- Tzelepi E, Giakkoupi P, Sofianou D, Loukova V, Kemeroglou A and Tsakris A (2000):** Detection of extended-spectrum beta-lactamases in clinical isolates of *Enterobacter cloacae* and *Enterobacter aerogenes*. *J. Clin. Microbiol.* **38**:542-6.
- Tzeng Y L, Ambrose K D, Zughaier S, Zhou X, Miller Y K, Shafer W M and Stephens D S (2005):** Cationic antimicrobial peptide resistance in *Neisseria meningitides*. *J. Bacteriol.* **187**: 5387 –96.
- Urban C, Segal-Maurer S and Rahal J J (2003):** Considerations in control and treatment of nosocomial infections due to multidrug-resistant *Acinetobacter baumannii*. *Clin. Infect. Dis.* **36**:1268-74.
- Vakulenko S B and Mobashery S (2003):** Versatility of aminoglycosides and prospects for their future. *Clin. Microbiol. Rev.* **16**: 430 –50.

- Valencia R, Arroyo L A and Conde M (2009):** Nosocomial outbreak of infection with pan-drug-resistant *Acinetobacter baumannii* in a tertiary care university hospital. *Infect Control Hosp Epidemiol.* **30**:257-63.
- Vandenesch F, Naimi T and Enright M C (2003):** Community- acquired methicillin-resistant *Staphylococcus aureus* carrying Panton-Valentine leukocidin genes: worldwide emergence. *Emerging Infectious Diseases.* **9**: 978–84.
- Van Enk R A and Thompson K D (1992):** Use of a primary isolation medium for recovery of methicilin-resistant *Staphylococcus aureus*. *J. of Clin. Microbiol.* **30**:504-5.
- Van Hal S J, Stark D, Lockwood B, Marriott D and Harkness J (2007):** Methicillin-Resistant *Staphylococcus aureus* (MRSA) Detection : Comparison of Two Molecular Methods (IDI-MRSA PCR Assay and GenoType MRSA Direct PCR Assay) with Three Selective MRSA Agars (MRSA ID, MRSASelect, and CHROMagar MRSA) for Use with Infection-Control Swabs. *J. Clin. Microbiol.* **45**(8):2486-90.
- VanSaene H K F, Reilly N J, DeSilvestre A and Nardi G (2005):** Antibiotic policies in the intensive care unit: *Infection Control in Intensive Care Units. Topics in Anaesthesia and Critical Care*, section three, springer. p.231-46
- Varela C, Oliver A, Coque T M, Baquero F and Canton R (2001):** Prevalence of extended-spectrum beta-lactamases in group-1 beta-lactamase-producing isolates. *Clin. Microbiol. Infect.* **7**:278-82.

- Vergis E N, Hayden M K, Chow J W, Snyderman D R, Zervos M J and Linden P K (2001):** Determinants of vancomycin resistance and mortality rates in *enterococcal* bacteremia. A prospective multicenter study. *Ann. Intern. Med.* **135**:484–92.
- Walsh T R, Neville WA, Haran M H, Tolson D, Payne DJ, Bateson J H, MacGowan A P, and Bennett P M (1998):** Nucleotide and amino acid sequences of the metallo- β -lactamase, ImiS, from *Aeromonas veronii* bv. sobria. *Antimicrob. Agents Chemother.* **42**:436-9
- Walsh T R, Bolmstrom A, Qwarnstrom A and Gales A (2002):** Evaluation of a new E test for detecting metallo- β -lactamases in routine clinical testing. *J. Clin. Microbiol.* **40**:2755-9.
- Walsh T R, Toleman M A, Poirel L, and Nordmann P (2005):** Metallo- β -Lactamases: the Quiet before the Storm? *American Society for Microbiology. Clin. Microbiol. Rev.* **18**(2): 306–25.
- Warren J R, Farmer J J, Dewhirst F E, Birkhead K, Zembower T, Peterson L R, Sims L (2000):** Outbreak of nosocomial infections due to extended spectrum beta lactamase producing strains. *J. clin. Microbiol.* **38**: 3946 – 52.
- Webb E C (1984):** Enzyme nomenclature. Academic Press Inc. (London) Ltd.1: 366- 74
- Weigel L M, Clewell D B, Gill S R, Clark N C, McDougal L K, Flannagan S E, Kolonay J F, Shetty J, Killgore G E and Tenover F C (2003):** Genetic Analysis of a High-Level Vancomycin-Resistant Isolate of *Staphylococcus aureus*. *Science*, November. **302** (5650): 1569 –71.

- Weisenberg S A, Morgan D J, Espinal-Witter R and Larone D H (2009):** Clinical outcomes of patients with *Klebsiella pneumoniae*: carbapenemase-producing *K. pneumoniae* after treatment with imipenem or meropenem. *Diagn. Microbiol. Infect. Dis.* **64**: 233-5.
- White D G, Hudson C, Maurer J J, Ayers S, Zhao S, Lee M D, Bolton L, Foley T and Sherwood J (2000):** Characterization of chloramphenicol and florfenicol resistance in *Escherichia coli* associated with bovine diarrhea. *J. Clin. Microbiol.* **38**: 4593 –8.
- White P A, McIver C J and Rawlinson W D (2001):** Integrons and gene cassettes in the Enterobacteriaceae. *Antimicrob. Agents Chemother.* **45**: 2658 – 61.
- Wiener J, Quinn J P, Bradford P A, Goering R V, Nathan C, Bush K, and Weinstein R A (1999):** Multiple antibiotic-resistant *Klebsiellae* and *Escherichia coli* in nursing homes. *JAMA.* **281**:517-23.
- Wierzbowski A K, Swedlo D, Nichol K, Hisanaga T, Rusen J and Hoban D (2004):** Resistance genotypes among macrolide resistant *Streptococcus pneumoniae* isolated in Canada between 1997 and 2003 [Abstract C2 -821]. In: Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington; Oct 30 – Nov 2.
- Woodford N, Tierno P M Jr and Young K (2004):** Outbreak of *Klebsiella pneumoniae* producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. *Antimicrob. Agents Chemother.* **48**:4793-9.

Wright H T and Reynolds K A (2007): Antibacterial targets in fatty acid biosynthesis. *Current Opinion in Microbiology*. **10**(Issue 5):447-53

WHO (2005): World health Organization. Global Strategy for Containment of Antimicrobial resistance. Available from http://www.wpro.who.int/health_topics/antimicrobial_resistance.

WHO (2007): World health Organization. Model List (Essential medicines); 15th edition. Available from: <http://www.who.int/medicines/publications/EssMedlist15.pdf>.

Yalaz M, Cetin H, Akisu M, Aydemir S and Tunger A (2006): Neonatal nosocomial sepsis in a level-III NICU: Evaluation of the causative agents and antimicrobial susceptibilities. *Turkish Journal of Pediatrics*. **48**(1): 13-18.

Yamane, Wachino J, Doi Y, Kurokawa H and Arakawa Y (2005): Global spread of multiple aminoglycoside resistance genes. *Emerg. Infect. Dis.* **11**: 951 –53.

Yan J J, Wu J J, Tsai S H and Chuang C L (2004): Comparison of the double-disc, combined disc, and Etest methods for detecting metallo- β -lactamases in gram-negative bacilli. *Diagn. Microbiol. Infect. Dis.* **49**:5-11.

Yan K G and Guglielmo B J (2007): Diagnosis and treatment of extended – spectrum and AmpC beta – lactamase – producing organisms. *The Annals of pharmacotherapy* , Sep. **41** (issue 9): 1427 – 35.

Yen Tan T , Hsu L Y, Koh T H , Lily S Y Ng, Krishnan N P, Raymond T P Lin and Jureen R (2008): Antibiotic Resistance in Gram-negative

- Bacilli: A Singapore Perspective. Ann. Acad. Med. Singapore. **37**:819-25
- Yigit H, Queenan A M, Anderson G J, Domenech-Sanchez A, Biddle J W, Steward C D, Alberti S, Bush K and Tenover F C (2001):** Novel carbapenem-hydrolyzing β -lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. Antimicrob. Agents Chemother. **45**:1151-61.
- Yong D, Lee K, Yum J H, Shin H B, Rossolini G M, and Chong Y (2002):** Imipenem-EDTA disc method for differentiation of metallo- β -lactamase-producing clinical isolates of *Pseudomonas spp.* and *Acinetobacter spp.* J. Clin. Microbiol. **40**:3798-3801.
- Yu C, Brasso W, Holliday D, Tung B and Sinha J (1999):** Detection of oxacillin resistance in clinical *Staphylococcus species* with the Phoenix system. Clinical Microbiology and Infection. **5**(Suppl. 3): 94.
- Zabransky R J, Dinuzzo A R and Woods G L (1995):** Detection of vancomycin resistance in *enterococci* by the Alamar MIC system. J. Clin. Microbiol., **33**:791–3.
- Zhao – Wei T, Long – qi Z, Wei-Hong W, and Bai- Nian S (2008):** Analysis the infection and antimicrobial resistance of *Aeromonas hydrophila*. Huzhou City Central Hospital, Huzhou, China .Chinese Journal of Microecology. **1**: 28
- Ziha – Zarifi I, Llanes C, Kohler T, Pechere J C and Plesiat P (1999):** In vivo emergence of multidrug – resistant mutants of *pseudomonas aeruginosa* over expressing the active efflux system MexA – MexB- OprM. Antimicrob. Agents Chemother. **43**: 287 –91.

References